Impairment of BRCA function in OC has proven to predict response to platinum-based chemotherapy and PARP-inhibitors; consequently, BRCA1/2 analysis is being routinely used to inform the medical treatment of OC patients [24,25,26]; the advantage of identifying also somatic BRCA1/2 mutations has led to the recommendation that BRCA sequencing be performed on tumor tissue. This evidence concerns the gene BRCA1 and neoplasm.